Investor Presentation | October 11th 2019CSE: ABCS | OTCQX: ABAHF

ADVANCED RELIEF Powered by Nature™

ADVANCED RELIEF Powered by Nature™

B2C B2B

Leading Topical Brands

GENERAL

Investors and prospective investors should rely only on the information contained in the continuous disclosure filings (the

“Filings”) of Abacus Health Products, Inc. (the “Company” or “Abacus”), including the information contained in the annual

information form of the Company dated April 12, 2019 (the “Annual Information Form”), which are available under the

Company’s SEDAR profile at www.sedar.com. This presentation is qualified in its entirety by reference to, and must be

read in conjunction with, the information contained in the Filings. An investor or prospective investor is not entitled to rely

on parts of the information contained in this presentation to the exclusion of others, and the Company is not authorized to

provide different or additional information. Unless otherwise specified, all monetary amounts in this presentation are in

United States dollars.

An investment in the securities discussed in this presentation is speculative and subject to a number of risks that should

be considered by an investor or prospective investor. Investors and prospective investors should carefully consider the

risks described in the Filings. This presentation does not constitute an offering of securities and the information contained

herein is subject to the information contained in the Company’s Filings.

Disclaimer

FORWARD-LOOKING INFORMATIONThis presentation contains forward-looking information or statements (collectively, “forward-looking information” within the

meaning of applicable securities laws. Forward-looking information may relate to the Company’s future outlook and

anticipated events, plans or results, and may include information regarding the Company’s objectives, goals, strategies,

future revenue or performance and capital expenditures, and other information that is not historical information.

Particularly, information regarding the Company’s expectations of performance, achievements, prospects or opportunities,

or the markets in which the Company operates, is forward-looking information. Forward-looking information can often be

identified by the use of terminology such as “believe,” “anticipate,” “plan,” “expect,” “pending,” “in process,” “intend,”

“estimate,” “project,” “may,” “will,” “should,” “would,” “could,” “can,” the negatives thereof, variations thereon and similar

expressions. In addition, any statements that refer to expectations, intentions, projections or other characterizations of

future events or circumstances contain forward-looking information. Statements containing forward-looking information are

not historical facts but instead represent management’s expectations, estimates and projections regarding future events or

circumstances.

The forward-looking information contained in this presentation is based on the Company’s opinions, estimates and

assumptions in light of management’s experience and perception of historical trends, current conditions and expected

future developments, as well as other factors that management currently believes are appropriate and reasonable in the

circumstances. Despite a careful process to prepare and review the forward-looking information, there can be no

assurance that the underlying opinions, estimates and assumptions will prove to be correct.

FORWARD-LOOKING INFORMATION CONTINUEDRisk factors that could cause actual results to differ materially from forward-looking information in this presentation include: potential

changes to state or federal laws pertaining to Industrial Hemp; risks associated with numerous laws and regulations; international

regulatory risks; uncertainty caused by potential changes to the current regulatory framework; receipt of necessary regulatory approvals

and permits; DEA jurisdiction over hemp extracts or CBD; environmental, health and safety laws; anti-money laundering laws and

regulations; banking; denial of deductibility of certain expenses; liability for actions of employees, contractors and consultants; reliance on

third party suppliers, service providers and distributors; compliance by manufacturers with cGMP requirements; reliance on key products;

industry competition; intra-industry competition; other conflicts of interest; changing consumer preferences and customer retention;

maintaining and promoting the Company’s brand; unfavourable publicity or consumer perception; inability to sustain pricing models;

reliance on key inputs; management of growth; product viability; success of quality control systems; product recalls; product liability; key

officers and employees; product returns; inability to protect intellectual property; domestic supply risk; intellectual property claims; litigation;

trade secrets may be difficult to protect; transportation risk; effectiveness and efficiency of advertising and promotional expenditures;

obtaining insurance; additional financings; risks related to acquiring companies; use of customer information and other personal and

confidential information; data security breaches; global economic uncertainty; emerging industry; inability to renew leases; potential

volatility of price of securities; holding company structure; risks related to potential changes in definition of “foreign private issuer”;

increased costs as a result of becoming a reporting issuer; financial reporting and other public issuer requirements; impact of future sales

by existing shareholders; influence of the significant shareholders; and any other risks that may be included in the Filings, including under

“Risk Factors and Uncertainties” in the Annual Information Form. Although management has attempted to identify important risk factors

that could cause actual results to differ materially from those contained in the forward-looking information in this presentation, there may be

other risk factors not presently known to the Company or that the Company presently believes are not material that could also cause actual

results or future events to differ materially from those expressed in such forward-looking information in this presentation. There can be no

assurance that such information will prove to be accurate, as actual results and future events could differ materially from those anticipated

in such information. Accordingly, readers and viewers should not place undue reliance on forward-looking information, which speaks only

as of the date made. The forward-looking information contained in this presentation represents the Company’s expectations as of the date

of this presentation or the date indicated, regardless of the time of delivery of the presentation. The Company disclaims any intention,

obligation or undertaking to update or revise any forward-looking information, whether as a result of new information, future events or

otherwise, except as required under applicable securities laws.

All of the forward-looking information contained in this presentation is expressly qualified by the foregoing cautionary statements. Investors

and potential investors should consult their own professional advisors to ascertain and assess the income tax, legal, risk factors and other

aspects of their investment or potential investment in the Company and should carefully consider the risks described in the Filings.

NO THIRD PARTY VERIFICATIONThe information contained in the presentation, including market information from third parties, has not been independently verified and no

representation or warranty, express or implied, is made as to, and no reliance should be placed on, the fairness, accuracy, completeness

or correctness of the information or opinions expressed herein.

Leading BrandsLeading brands with line of OTC pain relief and skincare products containing CBD hemp extract and oil

DistributionEstablished and growing distribution in major national retailers (B2C), health care practitioner offices (B2B), ecommerce platforms

Proprietary ProductsPatent pending formulations to provide fast and effective relief

Market OpportunityAbacus’ brands cater to

$7.4 billion pain relief market1

and $2.6 billion skincare

market2

1 Allied Market Research. (2018). Global Topical Pain Relief Market: Opportunities and Forecasts, 2018-2025. Portland, OR: Allied Analytics, LLP.2 American Academy of Dermatology Association; Estimated annual medical costs for Acne ($846 million), Eczema ($314 million) and Contact Dermatitis ($1,529 million).3 In-the-money fully diluted shares outstanding.; includes Proportionate Voting Shares and Subordinate Voting Shares, in-the-money Warrants and Options4 Based on closing share price as of October 11th, 2019 of CAD $6.00 converted at USD/CAD 1.335 Reflects cash balance as of June 30, 2019.

Investment Highlights

ITM FD Shares O/S3CSE: ABCS ITM FD Market Cap4 Cash5

US$103.6m22.9m US$32.3mOTCQX: ABAHF

4

Patent-pending formulations based on 15+ years of R&D by Aidance Scientific (former parent)

Utilizing active pharmaceuticalingredients, natural ingredients, essential oils, and CBD hemp extract and oil (Cannabis sativa L.)

Pharma Pedigree

OTC pharmaceutical-grade products

Produced in cGMP compliant facility by contract manufacturer (Aidance)

Production capacity of over 400,000 units/month - able to meet pent up demand

Proprietary Formulations Manufacturing & Quality

CBD MEDIC: Consumer Offering

6

Pain Relief Line:Arthritis, Back & Neck, Active Sport, Muscle & Joint, Foot Pain

Skincare Line:Acne, Eczema, Itch & Rash

Product Forms:Ointments, creams, pain sticks, sprays and massage oils

Distribution:~3,000 retail pharmacy and grocery locations across 23 states, including CVS

Opportunity:100,000 retail locations in the US food, drug and mass market (F/D/M)

Retail Presence

Current States with Retail Presence

Retail Locations

Current deployment

Total stores in deployed chains

Existing

3,000

22,000

Carried in 18 retail chains across 24 states

11

24

0

10

20

30

Q1 2019 Q2 2019

States Carrying CBDMEDIC

2000

3000

0

1000

2000

3000

Q1 2019 Q2 2019

Retail Locations Carrying CBDMEDIC

CBD CLINIC: Health Practitioner Offering

Pain Relief Line:High strength formulations to address varying levels of pain

Market:Used in-practice and sold in over 12,000 practitioner offices

Product Forms: Ointments, pain sticks and massage oils

Distribution:Leading national distributors

Opportunity:Over 800,000 practitioners in the US

1 Allied Market Research. (2018). Global Topical Pain Relief Market: Opportunities and Forecasts, 2018-2025. Portland, OR: Allied Analytics, LLP.2 American Academy of Dermatology Association; Report “The burden of skin disease in the United States.”3 American Academy of Dermatology Association; Estimated annual medical costs and number of affected people for Acne ($846 million), Eczema ($314 million) and Contact Dermatitis ($1,529 million).

Market Opportunity

Market Segments

Number of Americans affected

Market Value

RX Market Challenges

OTC Market Challenges

Pain1 Skincare2,3

Acute & Chronic

100 million

$7.4 billion

High cost, poor tolerability, unfavorable side effects, concerns over long-term safety and abuse

Limited advancements in technology

Acne Eczema Itch & Rash

50 million 31 million 13 million

$2.6 billion

CBD CLINIC & CBDMEDIC offer powerful all-natural alternatives

Expand number of SKUs for various therapeutic indications

Expect to reach 5,000-6,000 retail locations by end of 2019

National marketing strategy to drive sales in retail locations

OTC formulation as competitive differentiator in the practitioner market

Leverage existing customer base for repeat purchases

Penetration of new practitioner segments

Brand Strategy

9/10 Health Care Practitioners who use CBD CLINIC recommend it over other topical analgesics1

CBDMEDIC brand generates highest revenue per store per month in CVS2

1 - Data is based on a third party survey with 253 respondents. Health Care Practitioners are 96% composed of Chiropractors, Message Therapists, Acupuncturists and Physical Therapists2 - Based on IRI industry data for the 13-week period ending August 11th 2019 for locations where CBDMEDIC is sold

Launch to major media platforms including TV and radio in select regions in Q3

Participation in industry events: NACDS Total Store Expo, The National by FCA, Pain Kllr, Paleo F(x), National Products Expo West

Marketing Initiatives

Partnered with Rob Gronkowski (Gronk) to increase CBDMEDIC brand awareness and launch a co-branded line of sports nutrition and wellness products

Began in-store advertising program in CVS with plans to extend to other retailers

Featured in prominent publications including GQ, Allure, Glamour and Well-Good

Continued partnership with celebrity fitness trainer and nutritionist expert Harley Pasternak

Development of additional products in new indications

Israeli subsidiary to identify and secure unique technologies

Focus on Canada, EU and Australia

Partner with local distributors and manufacturers

Investment in infrastructure and supply chain for scalability, redundancy and quality

Growth Strategy

Scalability R&D International Expansion Brand Expansion

Expanded line of pharma grade nutrition & wellness productsplanned to be introduced in 2020

Strong quarter-over-

quarter sales growth

Strong liquidity position

of US$32 million

Financial Profile

(US$ million)Q2

Jun 30, 2019Q2

Jun 30, 2018

Total Revenues 3.2 2.1

Gross Profit

Gross Margin

Abacus raised over US$40

million over the last

twelve months to support

growth and marketing

initiatives

2.0 1.2

61% 58%

Capitalization and Ownership

Figures in US$ million, unless otherwise statedShare Price as of: October 11th, 2019

1 Based on closing share price as of October 11th, 2019 of CAD $6.00 converted at USD/CAD 1.332 Includes Proportionate Voting Shares and Subordinate Voting Shares3 Includes in-the-money outstanding warrants and options

Share Price (US$)1 $4.51

Basic Shares Outstanding2 21.0

Basic Market Capitalization $94.7

In-the-money ("ITM") Securities3 1.9

Fully Diluted ITM Shares Outstanding 22.9

FD ITM Capitalization $103.6

Dr. Bharat Madhavan

Chief Technology Officer

Dr. Bharat Madhavan is a microbiologist holding several

international patents, specializing in R&D and Quality

Control/Assurance in the field of formulations and

Pharmaceutical Science.

Perry AntelmanChief Executive Officer

Perry has over 30 years of executive business

experience, funding, launching, and growing

companies in the chemical and medical

technology/pharmaceutical sectors.

Hank HagueChief Financial Officer

Prior to joining the company Hank was the CFO of

Foster Corporation. He served as CFO for Scott Brass a

Sun Capital Partners portfolio company. Hank has

worked in financial roles for Stanley Black & Decker,

Pitney Bowes, Medtronic, and The Gillette Company.

The Abacus team consists of seasoned executives, scientists and regulatory advisors.

Mark Bolling

Vice President of Sales

Mark has over 25 years of business development,

sales, and marketing experience spanning diverse

industries and product lines. He served as the

Vice President of Business Development –

Commercial Sales for PuraCap Pharmaceutical.

James BarkatVice President of Marketing

James most recently served as U.S. Marketing

Head – Digestive Health, at Sanofi Consumer

Health. He has over 20 years experience in the

over-the-counter pharmaceutical industry and has

marketed with 10 major U.S. retailers.

Phil Henderson

Senior Investment Director (Consultant)

Henderson and Company is a consulting practice

helping early stage and emerging companies with

critical strategic and operational issues, and interim

management. Phil has has successfully raised financing

with Angel, Institutional and Corporate investors.

Jonathan Conforti Vice President of Corporate Development

Jonathan has held senior roles in business development

and finance in the technology, life sciences and mineral

resource sectors. Prior to joining the company Jonathan

was Vice-President of Business Development at iMDsoft.

Management Team

Contact Information: Hank Hague, CFO | investorrelations@abacushp.com | 416-848-1457 | www.abacushp.com